Microvast Holdings announces departure of chief financial officer
Privia Health Group , Inc. (NASDAQ:PRVA), a $2.85 billion healthcare company with a GREAT financial health score according to InvestingPro, saw its CEO Parth Mehrotra sell shares of the company’s common stock valued at approximately $252,651. The transaction occurred on March 12, 2025, as per the company’s recent SEC Form 4 filing.
Mehrotra sold 10,514 shares at an average price of $24.03 per share, amid an 8.46% decline in the stock price over the past week. Following this transaction, he holds 469,381 shares directly in Privia Health Group. The sale was executed under a pre-established 10b5-1 trading plan, which allows company insiders to sell a predetermined number of shares at a specific time.
This transaction is part of routine trading activities and provides investors with a snapshot of insider trading activity within Privia Health Group. With analyst price targets ranging from $21 to $40, investors seeking deeper insights into insider trading patterns and comprehensive analysis can access the full Pro Research Report on InvestingPro.
In other recent news, Privia Health Group has made notable changes to its executive compensation structure, as reported in a recent SEC filing. Parth Mehrotra, a key executive at the company, will see his base salary increase to $650,000 starting March 2025, with eligibility for a performance bonus up to 125% of his salary and a long-term incentive award valued at $8 million. Meanwhile, several analyst firms have adjusted their price targets for Privia Health’s stock, reflecting confidence in the company’s future performance. Jefferies raised its target to $29, citing strong cash generation and minimal regulatory exposure, while maintaining a Buy rating. Canaccord Genuity also increased its target to $30, praising the company’s prudent business approach and consistent financial performance. JMP Securities adjusted its target to $29, noting Privia’s robust guidance for 2025 and diversified platform across payors and providers. Piper Sandler set a higher target of $40, highlighting Privia’s strategic approach to value-based care and its ability to maintain growth amid industry challenges. These developments underscore Privia Health’s strong positioning in the healthcare sector and its potential for continued growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.